- Home
- NEWS
- REGIONAL
- THIS WEEK'S PAPER
- BLOGS
- Multimedia
- OPINION
- A&E
- LISTS
- PEOPLE
- EVENTS
- Classifieds
- Subscribe
Eli Lilly and Co.
Eli Lilly's slumbering stock finally shows signs of life
May 14, 2011
Greg AndrewsIs it finally time to get some growth again out of a stock that since its debut on the public market 59 years ago has minted
thousands of millionaires?
MoreLilly drug to detect Alzheimer’s criticized by consumer group
May 11, 2011
Bloomberg NewsEli Lilly and Co.’s Amyvid, an experimental imaging agent to detect signs of Alzheimer’s disease in the brain,
shouldn’t be approved because of unreliable study results, a consumer-advocacy group said.
MoreTwo wins to bring Lilly modest sales
May 9, 2011
J.K. WallFinally, some new revenue. Eli Lilly and Co. will enjoy modest new sales later this year after U.S. regulators approved a
new diabetes drug developed by a partner company, and another company nears approval on a drug that will produce royalties
for the Indianapolis-based drugmaker.
MoreEli Lilly pledges $2.5 million to Mind Trust
May 5, 2011
J.K. WallEli Lilly and Co. plans to give $2.5 million toward a new fundraising campaign by the Mind Trust, an Indianapolis-based education
reform group.
MoreFDA OKs new diabetes pill from Lilly, Boehringer
May 2, 2011
IBJ Staff and Associated PressThe Food and Drug Administration says it has approved a new diabetes pill from Boehringer Ingelheim and Eli Lilly for patients
who can't control their blood sugar with older medicines.
MoreLilly teams with Medtronic on Parkinson's treatment
April 26, 2011
J.K. WallEli Lilly and Co. plans to use an implantable drug-delivery system made by Medtronic Inc. to precisely target patients'
brains with an experimental drug for Parkinson’s disease.
MoreLilly shareholders fail to remove anti-takeover measures
April 18, 2011
J.K. WallA proposal that would have weakened Eli Lilly and Co.’s defenses against an unwanted takeover failed to pass Monday
despite a large majority of shareholders voting to remove those barriers for the second straight year.
MoreAnalysts demand news on next Lilly blockbuster
April 18, 2011
J.K. WallEli Lilly and Co. spends a lot of time these days telling the rest of the story—how well it’s doing in areas not
connected to highly lucrative drugs about to see their patents expire. But for the most part, investors and analysts just
want to know when the next blockbuster will be coming.
MoreLilly shares falter after quarterly earnings report
April 18, 2011
J.K. WallEli Lilly and Co.’s first-quarter profit beat the expectations of Wall Street analysts, but its stock price slipped
anyway Monday morning, along with the broader market.
MoreCharges drive down first-quarter profit at Lilly
April 18, 2011
J.K. WallFirst-quarter profit fell at Eli Lilly and Co. as the company recorded restructuring charges due to its downsizing and higher
research costs as it tries to develop new drugs to help it shrug off its looming patent expirations.
MoreFDA wants further testing of Lilly pancreas drug
April 16, 2011
Associated PressEli Lilly and Co. Inc. said Friday that the FDA has asked the drugmaker to conduct another clinical trial of its proposed
pancreas drug before it resubmits an application to have the drug approved for sale.
MoreLilly’s Bydureon wins backing of European drug panel
April 15, 2011
Bloomberg NewsThe drug awaits final action by the European Commission, which has the authority to approve medicines for the European Union.
The Commission usually makes a decision on CHMP recommendations within two to three months.
MoreSix faces behind Indianapolis business Twitter handles
April 9, 2011
Gabrielle PoshadloMeet the people who tweet for Indianapolis Symphony Orchestra, AAA, Butler University and other local businesses.
MoreChina making big gains in drug R&D jobs state covets
April 9, 2011
Greg AndrewsThe total annual cost for one researcher at Lilly might run $300,000 to $350,000 a year. The figure at Crown Bioscience is
one-third of that, said a company executive.
MoreAntidepressants linked to narrowed arteries
April 4, 2011
The study included Eli Lilly and Co. drug Cymbalta, which racked up sales of $3.5 billion last year for the Indianapolis-based
drugmaker.
MoreDrugmaker Lilly launches global service program
March 31, 2011
Associated PressEli Lilly and Co. is starting a service program that sends employees around the world to help developing communities and learn
about other cultures, as the drugmaker looks to international markets.
MoreDemographic shift steers Lilly's Asian operations
March 26, 2011
Greg AndrewsChina remains a small market for Eli Lilly and Co. It generated $320 million in sales for the company in 2010, just 1.3 percent
of its $23 billion in sales worldwide. But Lilly has big ambitions in China and is racing to capitalize on its rapid economic
growth.
MoreDrugmakers call off animal-health deal, possible asset sale
March 22, 2011
IBJ Staff and Bloomberg NewsDrugmakers Merck & Co. and Sanofi-Aventis SA have abandoned plans to combine their animal-health businesses after wrestling
with regulators for a year over potential divestitures.
Indianapolis-based Eli Lilly and Co. was among a list of possible suitors for about $1 billion in assets the two companies
considered selling.
MorePROXY CORNER: Eli Lilly and Co.
March 19, 2011
IBJ StaffEli Lilly and Co., Lilly Corporate Center, Indianapolis, 46285 (www.lilly.com) discovers, develops, manufactures and sells
pharmaceutical products for humans and animals.
MoreRegulators delay approval of Lilly's Alzheimer’s screen
March 18, 2011
Bloomberg NewsThe Food and Drug Administration said Lilly needs to create a training program to ensure brain scans are interpreted properly.
MoreTrade agency to probe Lilly's infringement claim
March 17, 2011
Bloomberg NewsEli Lilly and Co.’s patent-infringement claim over Hospira Inc.’s generic version of the cancer treatment Gemzar will be investigated
by a U.S. trade agency with the power to block imports of the copycat drug.
MoreLechleiter: After the deluge, we'll be fine
March 16, 2011
J.K. WallEli Lilly and Co. CEO John Lechleiter visited Japan last week—three days before the massive earthquake—to deliver
his tried-and-true message: Drug companies need to reinvent invention, governments needs to support innovation, and Lilly
will be just fine after it has sustained the damage of the next three years.
MoreLilly agrees to buy European animal health company
March 14, 2011
J.K. WallElanco, the animal health division of Eli Lilly and Co., has agreed to acquire Jannsen Animal Health, a subsidiary of New
Jersey-based Johnson & Johnson, pending regulatory approval. Financial terms of the deal were not disclosed.
MoreLilly suffers another bruise from Novo
March 9, 2011
J.K. WallThe failure of its drug Bydureon to match the performance of Novo’s Victoza trims but doesn’t kill sales prospects for the
highly touted diabetes drug.
MoreLilly's Bydureon falls short of competitor in study
March 3, 2011
Bloomberg NewsBydureon, the diabetes drug being developed by Amylin Pharmaceuticals Inc., Eli Lilly and Co. and Alkermes Inc., didn’t
control the disease better than Novo Nordisk A/S’s Victoza in a study.
More
Sponsored by
ADVERTISEMENT
on Facebook & Twitter
on Facebook & Twitter
 Follow IBJ's Tweets on these topics: |
||
| @IBJNews | @Propertylines | @IBJTheScore |
| @IBJArts | @IBJHealthcare | @IBJDining |
| @IBJLists | @IBJSmallbiz | |
ADVERTISEMENT
Back to TopCopyright © All Rights Reserved. Privacy Policy | Terms of Use.
Design, CMS, Hosting & Web Development :: ePublishing.
Additional Hosting & Delivery by
Saw the Indy Men's Chorus "Music of Gilbert & Sullivan" at the Indiana Historical Society on Sunday evening.
Temporary workers are not "tools" they are people and companies that keep large amounts of temp staff are cheating.
I miss having them around. I hope one of their stores is in the general Meridian/86th Street area. I will make good use of it.
The Fringe! Plus, the simple fact that there are so many local faves in such close proximity to each other.
I remenber, watching the toll road, being built, through South Bend, when I was 10 years old. I believe, back then that it was estimated, that the toll road, would be paid for in 20 years and then it would be free. I am now 71, what happened? Since the power is in the people, by that, I mean that, we the people are in total control of everything. I, suggest that no one ever use the toll road again, let it go broke. We the people can control the price of everything, from groceries to gas, if we would just do it. If we don't pay the asking price, the sellers will lower the price and if we wait awhile, they will lower the price to what we accept as reasonable. I would like to know why a highway like interstate 94, is so well maintained, a much better highway, than the toll road, but has no tolls. I would also like to know why, a sitting governor, with a term limit, maximum of eight years, can lease, public property, for 75 years. Even though I have transponders in both of my trucks and will not be affected by the increase, I have been and will contine to avoid using the toll road. I make many trips from northern Indiana to Chicago, every year, and I prefer the better highway, I94!